PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor

Targeted biological therapies may achieve maximal therapeutic efficacy at doses below the maximum tolerated dose (MTD); therefore, the search for the MTD in clinical studies may not be ideal for these agents. Emactuzumab is an investigational monoclonal antibody that binds to and inhibits the activa...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Pharmacol Ther
Hoofdauteurs: Smart, Kevin, Bröske, Ann‐Marie, Rüttinger, Dominik, Mueller, Claudia, Phipps, Alex, Walz, Antje‐Christine, Ries, Carola, Baehner, Monika, Cannarile, Michael, Meneses‐Lorente, Georgina
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2020
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7589268/
https://ncbi.nlm.nih.gov/pubmed/32575160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1964
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items